Financial Snapshot
Revenues
Revenues
Revenue YoY Change
Revenues
Expenses
Cost Of Revenues
Gross Profit
Gross Profit Margin
Gross Profit
Selling, General & Admin Expense
Research & Development
Depreciation, Depletion & Amortization
SGA Expense to Gross Profit Ratio
R&D To Gross Profit Ratio
DDA To Gross Profit Ratio
Operating Expenses Total
Operating Profits/Loss
Operational Expenses
Interest Expenses
Interest Expenses To Operating Income %
Other Expense/Income
Interest & Other Expense/Income
Income/Loss
Pretax Income
Income Tax
Net Profits/Loss
Pretax Income YoY Change
Income Tax Rate
Net Profits/Loss YoY Change
Basic EPS
Net Income To Revenue Ratio
Pretax & Net Income
Assets & Liabilities
Cash & Short-Term Investments
Cash & Equivalents
Cash To Operating Expenses Ratio
Inventory
Receivables
Total Short-Term Assets
Property, Plant And Equipment
Long-Term Investments
Total Long-Term Assets
Total Assets
Net Income To Total Assets Percentage
Accounts Payable
Short-Term Debt
Long Term Debt Due
Total Short-Term Liabilities
Long-Term Debt
Other Long-Term Liabilities
Total Long-Term Liabilities
Total Liabilities
Short-Term To Long-Term Debt Ratio
Short-Term Assets To Debt Ratio
Long-Term Debt To Net Income Ratio
Assets & Liabilities
Ownership
Basic Shares Outstanding
Diluted Shares Outstanding
Preferred Stock
Treasury Stock Shares
Stock Issuance & Repurchase
Ownership Data
Return On Shareholders' Equity
Book Value
Free Cash Flow
Free Cash Flow YoY
Free Cash Flow Margin
Dividends
Dividends
Stock Price
About ORGANOVO HOLDINGS, INC.
Organovo Holdings, Inc. is engaged in the development of bioprinted human tissues that emulate human biology and disease. The company is headquartered in San Diego, California and currently employs 20 full-time employees. The company went IPO on 2013-08-02. The firm is focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues, as well as preclinical data. Its segments include research and development (R&D) and Mosaic Cell Sciences (Mosaic). The company is also focused on building high fidelity, 3D tissues that recapitulate key aspects of human disease. The company uses its proprietary technology to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease. Its Mosaic division to serve as a key source of certain primary human cells it utilizes in its research and development efforts. Its 3D human tissue platform is multifaceted. Its NovoGen Bioprinters can also dispense pure hydrogel formulations, provided the physical properties of the hydrogel are compatible with the dispensing parameters.
Industry: Biological Products, (No Diagnostic Substances) Peers: Aileron Therapeutics, Inc. APPLIED GENETIC TECHNOLOGIES CORP ATHERSYS, INC / NEW Inhibitor Therapeutics, Inc. Metacrine, Inc. Tempest Therapeutics, Inc. NANOVIRICIDES, INC. OPGEN INC KINETA, INC./DE